Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
|Articles|June 29, 2018
Pharm Exec Talks Partnerships with Sanofi
Author(s)Michelle Maskaly
Hear what Sanofi looks for when they decide to form a partnership with another company.
Advertisement
Adam Keeney, head, Sanofi Genzyme Business Development, shares what the company looks when they decide to form a partnership with another company.
Pharm Exec interviewed him at the June 2018 BIO International Convention in Boston.
Advertisement
Related to this article
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
2
FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy
3
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
4
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
5